benefit of magnesium dietary supplement

    mag-ox 400: magnesium oxide dietary supplement



Medical Links
Med-Line Search
Harcourt Health Sciences
American Heart Journal
Hypertension Journal
Physican's PDR.NET
Phamacist's Drug Topics Journal
PDR's Getting Well Network
NIH Clinical Center - Facts about Dietary Supplements
The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7)
Medline health information — Magnesium supplements

For Healthcare Professionals: Medical/Clinical Information

Clinical Study Abstracts

Beneficial antithrombotic effects of the association of pharmacological oral magnesium therapy with aspirin in coronary heart disease patients.
Shechter M, Merz CN, Paul-Labrador M, Meisel SR, Rude RK, Molloy MD, Dwyer JH, Shah PK, Kaul S. (Magnes Res 2000 Dec;13(4):275-84.) Copyright © 2000 by PubMed.)

Abstract: The use of magnesium in the treatment of acute myocardial infarction remains controversial despite preliminary experimental evidence that magnesium plays a beneficial role as a regulator of thrombosis. The aim of our study was to determine whether oral magnesium treatment inhibits platelet-dependent thrombosis (PDT) in stable patients with coronary artery disease (CAD). In a randomized prospective, double-blind, cross-over and placebo controlled study, 42 patients with stable CAD (37 men, 5 women, mean age 68 +/- 9 years) on aspirin received either magnesium oxide tablets (800-1,200 mg/day) or placebo for 3 months (Phase 1) followed by a 4-week washout period, and the cross-over treatment for 3 months (Phase 2). PDT, platelet aggregation, platelet P-selectin flow-cytometry, monocyte tissue factor procoagulant activity (TF-PCA) and adhesion molecules density were assessed before and after each phase. PDT was evaluated by an ex-vivo perfusion model using the Badimon chamber. Median PDT was significantly reduced by 35 percent in patients who received magnesium versus placebo (D change from baseline: -24 vs. 26 microm2/mm; p = 0.02, respectively). There was no significant effect of magnesium treatment on platelet aggregation, P-selectin expression, monocyte TF-PCA or adhesion molecules. Oral magnesium treatment inhibits PDT in patients with stable CAD. This effect appears to be independent of platelet aggregation or P-selectin expression, and is evident despite aspirin therapy. These findings suggest a potential mechanism whereby magnesium may beneficially alter outcomes in patients with CAD. Get Complete Article

Back to Clinical Study Abstracts

If you would like more information on Magnesium research, click here.



Blaine pharmaceutical company
For more information
call 1.800.633.9353 or
click here.

Are You at Risk?  I  Benefits of Magnesium  I  Why Blaine Mag-Ox 400?
FAQs  I  Healthcare Professionals  I  Contact Us  I  Site Map  I  Home Page